NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Post-Exposure Prophylaxis in Health Care Workers

CompletedPhase 4

Sponsor: Henry Ford Health System

Conditions: Human Immunodeficiency Virus

Interventions: emtricitabine/tenofovir disoproxil fumarate

Countries: United States

Objective: The objective of this study is to determine the safety and tolerability of Post-exposure Prophylaxis (PEP) with a regimen of Truvada + Kaletra among health care workers (HCWs) at Henry Ford Hospital. Hypothesis: Raltegravir is safe and better tolerated compared with Kaletra, each in combination with Truvada, as assessed by review of completion rates of PEP and also review of completed safety data.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Adult (at least 18 years of age)employees of HFH
* History of occupational exposure to bodily fluids
* Negative HIV test
* The ability to understand a written informed consent form, which must be obtained prior to initiation of any study procedures

Exclusion Criteria:

* Positive pregnancy test
* Females who are breastfeeding
* History of renal disease
* Contraindication for treating patient with components of PEP regimen
* Greater than one dose of PEP medication for this exposure event

Locations (1)

Detroit, Michigan, United States